AURKA Contributes to Neutrophil Activation and NETosis in Chronic Rhinosinusitis with Nasal Polyps
Ru Tang, Xiao Wu, Yuxin Lai, Zhihan Liu et autres
0 citationsInflammation
Feng Liu
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
57Publications signalées
832Citations signalées
5Affiliations récentes
Institutions déclarées
Domaines associés
Advanced Breast Cancer TherapiesMicroRNA in disease regulationCancer-related molecular mechanisms researchCircular RNAs in diseasesCancer-related Molecular Pathways
Publications récentes
Development and validation of an integrated machine learning model for recurrence-free survival prediction in clear cell renal cell carcinoma
Yun-Lian Wang, Feng Liu, Qianbiao Gu, Qiang Liu et autres
0 citationsTranslational Oncology
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor–Resistant HR+/HER2− Breast Cancer
Dejan Juric, Kazi Nazrul Islam, Ioanna‐Maria Gkotinakou, A. Zheng et autres
0 citationsCancer Research
Figure 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
Supplementary Table S3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
Supplementary Figure S3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
Supplementary Table S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
Supplementary Figure S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
Supplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.